Cambridge Investment Research Advisors’s Gamida Cell Ltd. Ordinary Shares GMDA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GMDA Stock Details GMDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-72,575	Closed	-$30K	–	3418
2023 Q4	$30K	Buy	72,575 +35,000	+93%	+$19.8K	﹤0.01%	3127
2023 Q3	$39K	Buy	37,575 +3,500	+10%	+$4.47K	﹤0.01%	3056
2023 Q2	$66K	Buy	34,075 +15,000	+79%	+$25.8K	﹤0.01%	3062
2023 Q1	$15K	Hold	19,075	–	–	﹤0.01%	3118
2022 Q4	$25K	Buy	+19,075	New	+$30.2K	﹤0.01%	3030

Other funds holding GMDA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LIM

Leavell Investment Management Mobile, Alabama $2.74B AUM 26.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Cambridge Investment Research Advisors's GMDA Position: Q1 2024 in Review

Cambridge Investment Research Advisors sold out of Gamida Cell Ltd. Ordinary Shares (GMDA) in Q1 2024, closing a stake of 72,575 shares — an estimated $30K sold.

Cambridge Investment Research Advisors first reported a position in GMDA in Q4 2022 and held it in 5 quarters. The position peaked at $66K in Q2 2023. 51 funds tracked by Wall St. Rank hold GMDA as of Q1 2024.

Cambridge Investment Research Advisors reported no remaining Gamida Cell Ltd. Ordinary Shares position as of Q1 2024 after selling out during the quarter.
Cambridge Investment Research Advisors sold 72,575 Gamida Cell Ltd. Ordinary Shares shares in Q1 2024, an estimated $30K.
Cambridge Investment Research Advisors first reported a position in Gamida Cell Ltd. Ordinary Shares in Q4 2022 and held it in 5 quarters.
Cambridge Investment Research Advisors's Gamida Cell Ltd. Ordinary Shares position peaked at $66K in Q2 2023.
51 funds tracked by Wall St. Rank held Gamida Cell Ltd. Ordinary Shares as of Q1 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.